GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
